CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel oncology therapeutics. Headquartered in South San Francisco, California, the company utilizes its proprietary Probody technology platform to create conditionally activated biologics designed to target tumor microenvironments while minimizing damage to healthy tissue. Its pipeline includes antibody-drug conjugates (ADCs), T-cell engaging bispecifics, and cytokine therapies aimed at treating various forms of cancer, such as colorectal cancer. CytomX does not currently have approved commercial products and generates revenue primarily through strategic research and development collaborations with major pharmaceutical companies, including Amgen, Astellas, Bristol Myers Squibb, and Moderna. The company's lead clinical candidates include Varseta-M (CX-2051), an EpCAM-directed ADC, and CX-801, a masked interferon alpha-2b.
